Bamco Inc. NY Has $2.20 Million Holdings in Inogen, Inc (INGN)
Bamco Inc. NY raised its holdings in shares of Inogen, Inc (NASDAQ:INGN) by 15.0% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 23,000 shares of the medical technology company’s stock after purchasing an additional 3,000 shares during the period. Bamco Inc. NY owned 0.11% of Inogen worth $2,195,000 at the end of the most recent quarter.
Several other hedge funds have also modified their holdings of INGN. BlackRock Inc. increased its position in shares of Inogen by 145,976.1% during the first quarter. BlackRock Inc. now owns 2,110,800 shares of the medical technology company’s stock worth $163,711,000 after purchasing an additional 2,109,355 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Inogen by 24.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after purchasing an additional 301,737 shares in the last quarter. New York State Common Retirement Fund boosted its position in shares of Inogen by 77.4% in the 2nd quarter. New York State Common Retirement Fund now owns 389,206 shares of the medical technology company’s stock worth $37,138,000 after purchasing an additional 169,778 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Inogen by 166.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 196,886 shares of the medical technology company’s stock worth $18,786,000 after purchasing an additional 122,913 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd acquired a new stake in shares of Inogen in the 1st quarter worth $9,139,000.
In related news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction on Tuesday, July 18th. The shares were sold at an average price of $94.21, for a total value of $235,525.00. Following the completion of the sale, the executive vice president now owns 4,833 shares in the company, valued at approximately $455,316.93. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction on Friday, July 14th. The shares were sold at an average price of $92.96, for a total transaction of $1,301,440.00. Following the completion of the sale, the director now owns 7,808 shares of the company’s stock, valued at approximately $725,831.68. The disclosure for this sale can be found here. Insiders sold 58,667 shares of company stock valued at $5,602,976 in the last 90 days. 5.31% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY WARNING: This story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2017/10/03/bamco-inc-ny-has-2-20-million-holdings-in-inogen-inc-ingn.html.
Shares of Inogen, Inc (NASDAQ:INGN) opened at 94.44 on Tuesday. Inogen, Inc has a one year low of $50.24 and a one year high of $105.35. The stock has a market capitalization of $1.96 billion, a price-to-earnings ratio of 81.98 and a beta of 1.00. The stock’s 50 day moving average is $97.92 and its 200-day moving average is $89.79.
Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same period in the previous year, the company earned $0.25 earnings per share. Inogen’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, equities research analysts predict that Inogen, Inc will post $1.21 EPS for the current fiscal year.
Several research analysts recently weighed in on the company. Zacks Investment Research downgraded Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Needham & Company LLC lowered their price target on Inogen from $108.00 to $96.00 and set a “strong-buy” rating for the company in a report on Thursday, June 8th. J P Morgan Chase & Co raised their price target on Inogen to $102.00 and gave the stock an “overweight” rating in a report on Monday, June 26th. Piper Jaffray Companies restated a “hold” rating and set a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Finally, BidaskClub upgraded Inogen from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 8th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. Inogen has a consensus rating of “Buy” and a consensus target price of $91.33.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.